Reducing hip fracture risk with risedronate in elderly women with established osteoporosis

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis

Tahir Masud1, Michael McClung2, Piet Geusens31Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, BelgiumBackground: There is limit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tahir Masud, Michael McClung, Piet Geusens
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
Hip fractures Risedronate Elderly Osteoporosis
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/a9759c5606924662a6865b74c2f5497e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a9759c5606924662a6865b74c2f5497e
record_format dspace
spelling oai:doaj.org-article:a9759c5606924662a6865b74c2f5497e2021-12-02T04:43:28ZReducing hip fracture risk with risedronate in elderly women with established osteoporosis1178-1998https://doaj.org/article/a9759c5606924662a6865b74c2f5497e2009-11-01T00:00:00Zhttps://www.dovepress.com/reducing-hip-fracture-risk-with-risedronate-in-elderly-women-with-esta-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Tahir Masud1, Michael McClung2, Piet Geusens31Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, BelgiumBackground: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged ≥70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score ≤ −2.5 and ≥ 1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.Keywords: osteoporosis, postmenopausal, hip fracture, risedronateTahir MasudMichael McClungPiet GeusensDove Medical PressarticleHip fractures Risedronate Elderly OsteoporosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 445-449 (2009)
institution DOAJ
collection DOAJ
language EN
topic Hip fractures Risedronate Elderly Osteoporosis
Geriatrics
RC952-954.6
spellingShingle Hip fractures Risedronate Elderly Osteoporosis
Geriatrics
RC952-954.6
Tahir Masud
Michael McClung
Piet Geusens
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
description Tahir Masud1, Michael McClung2, Piet Geusens31Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Oregon Osteoporosis Center, Portland, Oregon, USA; 3Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, BelgiumBackground: There is limited evidence to support the efficacy of current pharmaceutical agents in reducing the risk of hip fracture in older postmenopausal women with established osteoporosis.Objective: To clarify the efficacy of risedronate in reducing the risk of hip fracture in elderly postmenopausal women aged ≥70 years with established osteoporosis, i.e., those with bone mineral density-defined osteoporosis and a prevalent vertebral fracture.Methods: Post hoc analysis of the Hip Intervention Program (HIP) study, a randomized controlled trial comparing risedronate with placebo for reducing the risk of hip fracture in elderly women. Women aged 70 to 100 years with established osteoporosis (baseline femoral neck T-score ≤ −2.5 and ≥ 1 prior vertebral fracture) were included. The main outcome measure was 3-year hip fracture incidence in the risedronate and placebo groups.Results: A total of 1656 women met the inclusion criteria. After 3 years, hip fracture had occurred in 3.8% of risedronate-treated patients and 7.4% of placebo-treated patients (relative risk 0.54; 95% confidence interval 0.32–0.91; P = 0.019).Conclusion: Risedronate significantly reduced the risk of hip fracture in women aged up to 100 years with established osteoporosis.Keywords: osteoporosis, postmenopausal, hip fracture, risedronate
format article
author Tahir Masud
Michael McClung
Piet Geusens
author_facet Tahir Masud
Michael McClung
Piet Geusens
author_sort Tahir Masud
title Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
title_short Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
title_full Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
title_fullStr Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
title_full_unstemmed Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
title_sort reducing hip fracture risk with risedronate in elderly women with established osteoporosis
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/a9759c5606924662a6865b74c2f5497e
work_keys_str_mv AT tahirmasud reducinghipfractureriskwithrisedronateinelderlywomenwithestablishedosteoporosis
AT michaelmcclung reducinghipfractureriskwithrisedronateinelderlywomenwithestablishedosteoporosis
AT pietgeusens reducinghipfractureriskwithrisedronateinelderlywomenwithestablishedosteoporosis
_version_ 1718401096409415680

Ejemplares similares